Our model aimed to predict the chemotherapy benefit at elderly patients regardless of HR, HER2 status, and lymph node metastasis, and none genetic sequencing technics was required to complete the evaluation, which showed a broad application scope especially in economically disadvantaged areas. The gene discussed is HR; the disease is metastatic malignant neoplasm in the lymph nodes.